Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Addition of Vorinostat to Bortezomib Achieves Modest Improvement in Progression-Free Survival in Relapsed/Refractory Multiple Myeloma

March 20th 2012

Vorinostat added to bortezomib improved progression-free survival compared with bortezomib plus placebo in patients with relapsed/refractory multiple myeloma.

Dr. Wierda Discusses Watchful Waiting in CLL

March 14th 2012

Dr. William Wierda, from the MD Anderson Cancer Center, Discusses Watchful Waiting in CLL

Lymphoma During Pregnancy Can Be Safely Managed

March 12th 2012

Treatment of selected cases of localized lymphoma during the second and third trimester was associated with minimal maternal and fetal risk of complications.

Dr. Jagannath Discusses the VANTAGE Trials

March 12th 2012

Dr. Sundar Jagannath, from Mount Sinai Medical Center, Discusses the VANTAGE Trials

Nonmalignant Late Effects Pose Heavy Burden After Hematopoietic Cell Transplant

March 9th 2012

The burden of late complications after hematopoietic cell transplantation is high, and these late effects are associated with poor health and decreased functional status.

Dr. Ansell on Waldenstrom Macroglobulinemia Symptoms

March 8th 2012

Dr. Stephen Ansell from the Mayo Clinic in Minnesota Describes Waldenstrom Macroglobulinemia Symptoms

Noteworthy Research Spans Range of Malignancies

March 6th 2012

A review of interesting presentations from ASH that will stimulate highly clinically relevant discussion regarding disease management within the realm of the hematologic malignancies.

Dr. William Wierda Discusses Diagnosing CLL

March 5th 2012

Dr. William Wierda, from MD Anderson Cancer Center, on Diagnosing Chronic Lymphocytic Leukemia

Investigational Treatments for Multiple Myeloma

March 5th 2012

A closer look at 2 investigational agents, carlfilzomib and pomalidomide, that were featured at the 53rd American Society of Hematology annual meeting.

Dr. Mesa Discusses JAK Inhibitors for Myelofibrosis

March 2nd 2012

Dr. Ruben Mesa from the Mayo Clinic in Arizona Discusses JAK Inhibitors for Myelofibrosis

Dr. Jagannath on HDAC Inhibitors for Multiple Myeloma

February 29th 2012

Dr. Sundar Jagannath from the Tisch Cancer Institute Discusses HDAC Inhibitors for Multiple Myeloma

Dr. Steensma Discusses Iron Chelation Therapy for MDS

February 27th 2012

Dr. David Steensma, from Dana-Farber Cancer Institute, Discusses Iron Chelation Therapy for MDS

Managing Chronic Myeloid Leukemia Treatment

February 27th 2012

Certain characteristics of patients with CML can affect therapeutic outcomes.

New Model Helps Guide Treatment Options in CLL

February 27th 2012

A number of prognostic factors can help identify those at a high risk for CLL progression who may benefit from early intervention.

Dr. Erba Describes Proper Diagnostic Testing of CML

February 27th 2012

Dr. Harry Erba, from the University of Michigan Health System, Describes Proper Diagnostic Testing of CML

Dr. Dunleavy Discusses 3 Molecular Subtypes of DLBCL

February 24th 2012

Dr. Kieron Dunleavy from the National Cancer Institute Discusses 3 Molecular Subtypes of DLBCL

Current Trends in the Treatment of Newly Diagnosed Myeloma

February 24th 2012

A number of studies suggest that there is a right and wrong way to proceed with initial therapy and transplant eligibility for patients with multiple myeloma.

New Directions in Relapsed/Refractory Diffuse Large B-cell Lymphoma

February 24th 2012

Research has shown that DLBCL is heterogeneous, suggesting that patients with varying subtypes should receive different courses of treatment.

Dr. Ansell on Waldenstrom Macroglobulinemia Types

February 24th 2012

Dr. Stephen Ansell from the Mayo Clinic Describes WaldenstrÃ¶m Macroglobulinemia

Nilotinib Responses Better Than Imatinib in CML Trials

February 23rd 2012

Two phase III clinical trials showed that nilotinib continues to demonstrate more favorable molecular response levels in patients with Ph CML than imatinib mesylate.